J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 4, Number 4, August 2012, pages 251-258

Effects of 6-Month Sitagliptin Treatment on Glucose and Lipid Metabolism, Blood Pressure, Body Weight and Renal Function in Type 2 Diabetic Patients: A Chart-Based Analysis

Figure 1. A correlation between body mass index at baseline and change in body weight after the 6-month sitagliptin treatment. A statistical analysis was performed by the Pearson's correlation test. r indicates correlation coefficient.

**Table 1.** Clinical and Biochemical Characteristics of Subjects Studied
Presented values indicate mean ± S.D., e-GFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL-C, low-density lipoprotein-cholesterol; TG, triglyceride.
Number of subjects	220
Age (years old)	64.0 ± 14.0
Sex (male/female)	102/118
Body height (cm)	160.0 ± 8.9
Body weight (kg)	68.2 ± 15.8
Body mass index (kg/m²)	26.1 ± 5.3
Systolic blood pressure (mmHg)	126.7 ± 15.5
Diastolic blood pressure (mmHg)	69.8 ± 13.6
Plasma glucose (mg/dL)	185.5 ± 69.3
Hemoglobin A1c (%)	8.1 ± 1.3
Serum LDL-C (mg/dL)	105.0 ± 28.5
Serum TG (mg/dL)	176.7 ± 122.0
Serum HDL-C (mg/dL)	50.7 ± 14.6
e-GFR (mL/min./1.73m²)	77.4 ± 24.4

Table 1. Clinical and Biochemical Characteristics of Subjects Studied

Presented values indicate mean ± S.D., e-GFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL-C, low-density lipoprotein-cholesterol; TG, triglyceride.

Number of subjects

220

Age (years old)

64.0 ± 14.0

Sex (male/female)

102/118

Body height (cm)

160.0 ± 8.9

Body weight (kg)

68.2 ± 15.8

Body mass index (kg/m²)

26.1 ± 5.3

Systolic blood pressure (mmHg)

126.7 ± 15.5

Diastolic blood pressure (mmHg)

69.8 ± 13.6

Plasma glucose (mg/dL)

185.5 ± 69.3

Hemoglobin A1c (%)

8.1 ± 1.3

Serum LDL-C (mg/dL)

105.0 ± 28.5

Serum TG (mg/dL)

176.7 ± 122.0

Serum HDL-C (mg/dL)

50.7 ± 14.6

e-GFR (mL/min./1.73m²)

77.4 ± 24.4

**Table 2.** Other Oral Hypoglycemic Agents Which Subjects had Taken Before the Treatment With Sitagliptin
No other drugs	15
Sulfonyl urea	80
Biguanide	122
Pioglitazone	84
α-glucosidase inhibitor	80
Glinide	26

Table 2. Other Oral Hypoglycemic Agents Which Subjects had Taken Before the Treatment With Sitagliptin

No other drugs

Sulfonyl urea

Biguanide

122

Pioglitazone

α-glucosidase inhibitor

Glinide

**Table 3.** Changes in Clinical and Biochemical Data After 6 Month-Use of Sitagliptin
	Subjects studied (n)	Data after 6 month-use of sitagliptin	Changes compared with data before sitagliptin use	P value
Presented values indicate mean ± S.D. Statistical analyses have been done by Paired t Test. e-GFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL-C, low-density lipoprotein-cholesterol; NS, not statistically significant; TG, triglyceride.
Body weight (kg)	141	67.4 ± 15.8	-0.8 ± 3.7	< 0.001
Systolic blood pressure (mmHg)	169	125.2 ± 13.6	-1.5 ± 17.6	NS
Diastolic blood pressure (mmHg)	169	70.6 ± 11.0	+0.7 ± 12.4	NS
Plasma glucose (mg/dL)	195	175.7 ± 67.1	-9.8 ± 70.8	NS
Hemoglobin A1c (%)	169	7.5 ± 1.2	-0.6 ± 1.0	< 0.001
Serum LDL-C (mg/dL)	161	103.5 ± 25.6	-0.7 ± 27.6	NS
Serum TG (mg/dL)	161	169.4 ± 121.2	-7.3 ± 115.1	NS
Serum HDL-C (mg/dL)	161	49.8 ± 13.1	-0.9 ± 8.9	NS
e-GFR (mL/min./1.73m²)	199	75.9 ± 25.4	-1.5 ± 11.9	NS

Table 3. Changes in Clinical and Biochemical Data After 6 Month-Use of Sitagliptin

Subjects studied (n)

Data after 6 month-use of sitagliptin

Changes compared with data before sitagliptin use

P value

Presented values indicate mean ± S.D. Statistical analyses have been done by Paired t Test. e-GFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL-C, low-density lipoprotein-cholesterol; NS, not statistically significant; TG, triglyceride.

Body weight (kg)

141

67.4 ± 15.8

-0.8 ± 3.7

< 0.001

Systolic blood pressure (mmHg)

169

125.2 ± 13.6

-1.5 ± 17.6

Diastolic blood pressure (mmHg)

169

70.6 ± 11.0

+0.7 ± 12.4

Plasma glucose (mg/dL)

195

175.7 ± 67.1

-9.8 ± 70.8

Hemoglobin A1c (%)

169

7.5 ± 1.2

-0.6 ± 1.0

< 0.001

Serum LDL-C (mg/dL)

161

103.5 ± 25.6

-0.7 ± 27.6

Serum TG (mg/dL)

161

169.4 ± 121.2

-7.3 ± 115.1

Serum HDL-C (mg/dL)

161

49.8 ± 13.1

-0.9 ± 8.9

e-GFR (mL/min./1.73m²)

199

75.9 ± 25.4

-1.5 ± 11.9

**Table 4.** The Number and Percentage of Subjects Showed Increased, Unchanged, Decreased Values of Body Weight and Hemoglobin A1c After 6 Month-Use of Sitagliptin Compared with Values Before Sitagliptin Use
	Increased	Unchanged	Decreased
Body weight	46 (32.6%)	20 (14.2%)	75 (53.2%)
Hemoglobin A1c	44 (26.0%)	9 (5.3%)	116 (68.6%)

Table 4. The Number and Percentage of Subjects Showed Increased, Unchanged, Decreased Values of Body Weight and Hemoglobin A1c After 6 Month-Use of Sitagliptin Compared with Values Before Sitagliptin Use

Increased

Unchanged

Decreased

Body weight

46 (32.6%)

20 (14.2%)

75 (53.2%)

Hemoglobin A1c

44 (26.0%)

9 (5.3%)

116 (68.6%)

**Table 5.** Changes in Urinary Glucose and Protein After 6 Month-Use of Sitagliptin
	Before sitagliptin use (n)	After sitagliptin use (n)	P value
Statistical analyses have been done by Pearson's chi-squared test. NS, not statistically significant.
Urinary glucose
(-)	95	119	< 0.01
(+/-)	9	10	NS
(1+)	16	8	NS
(2+)	14	8	NS
(3+)	44	33	NS
Urinary protein
(-)	104	97	NS
(+/-)	39	42	NS
(1+)	22	22	NS
(2+)	9	13	NS
(3+)	4	4	NS

Table 5. Changes in Urinary Glucose and Protein After 6 Month-Use of Sitagliptin

Before sitagliptin use (n)

After sitagliptin use (n)

P value

Statistical analyses have been done by Pearson's chi-squared test. NS, not statistically significant.

Urinary glucose

(-)

119

< 0.01

(+/-)

(1+)

(2+)

(3+)

Urinary protein

(-)

104

(+/-)

(1+)

(2+)

(3+)